Fresenius Kabi USA, LLC
Fresenius Kabi USA, LLC, a prominent subsidiary of Fresenius Kabi AG, is headquartered in the United States and operates extensively across North America. Founded in 1996, the company has established itself as a leader in the healthcare industry, specialising in lifesaving medicines and technologies. Fresenius Kabi focuses on critical care, infusion therapy, and biosimilars, offering a diverse range of products that are distinguished by their quality and reliability. With a commitment to enhancing patient care, Fresenius Kabi has achieved significant milestones, including the development of innovative drug delivery systems and a robust portfolio of intravenous solutions. The company is recognised for its strong market position, consistently ranking among the top providers in its field, and is dedicated to advancing healthcare through sustainable practices and cutting-edge research.
DitchCarbon Score
How does Fresenius Kabi USA, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fresenius Kabi USA, LLC's score of 27 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fresenius Kabi USA, LLC's reported carbon emissions
Fresenius Kabi USA, LLC, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year. As a result, specific figures regarding their Scope 1, 2, or 3 emissions are not provided. In the absence of detailed emissions data, it is important to note that the company has not outlined any specific reduction targets or initiatives related to carbon emissions. This lack of information suggests that Fresenius Kabi USA may still be in the early stages of formalising its climate commitments or may not have publicly disclosed its strategies for addressing climate change. As the pharmaceutical and healthcare industry increasingly prioritises sustainability, it is essential for companies like Fresenius Kabi USA to establish clear climate goals and transparent reporting practices to align with global efforts to reduce greenhouse gas emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fresenius Kabi USA, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
